Brugada, Crisanta .
HRN: 26-73-11 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/21/2025
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
02/21/2025
02/28/2025
IV
4.5g
Q8H
SEPSIS
Waiting Final Action
Indication: Empiric Type of Infection: Unspecified Sepsis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes